Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

Recruiting now · Phase 1

Conditions studied: Idiopathic Pulmonary Fibrosis

In brief

The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.

Key facts

Study ID

NCT04362644

Run by

University of Alabama at Birmingham

People needed

10

Starts

2020-12-08

Expected to finish

2027-06-01

Last updated by the study team

2026-06-02

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 40-85 years old.
• A diagnosis of IPF that fulfills American Thoracic Society (ATS) / European Respiratory Society (ERS) 2018 consensus criteria within 5 years.
• Ability and willingness to give informed consent and adhere to study requirements.
• Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) >0.70.
• High or mixed affinity binder for TSPO ligands based on genotyping for single-nucleotide polymorphism (SNP)rs6971.

You may not qualify if…

• Acute exacerbation of IPF within <30 days
• Diagnosis of Diabetes Mellitus (Type 1 or Type 2).
• Diagnoses of current infection by clinical or microbial assessments.
• Treatment for >14 days within the preceding month with >20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant.
• Subjects with prior radiation therapy to the thorax.
• Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration.
• Severe cardiovascular disease, defined as any of the following within the preceding 12 weeks: acute myocardial infarction or unstable angina, a coronary revascularization procedure, or stroke.
• Subjects with known liver disease.
• Diagnosis of any active cancer with the exception of basal cell carcinoma of skin.
• Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.
• Active cigarette smoking or vaping

Where it is running

• The University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.